{"abstract":"This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR part 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive evaluation option license to practice the inventions embodied in U.S. Patent Application 61/040,005 entitled \"Human Monoclonal Antibodies Specific for Mesothelin\" [HHS Ref. E-079-2008/0- US-01], PCT Application PCT/US2009/038228 entitled \"Human Monoclonal Antibody Against Mesothelin\" [HHS Ref. E-079-2008/0-PCT-02], Australian patent application AU 2009228361 entitled \"Human Monoclonal Antibody Against Mesothelin\" [HHS Ref. E-079-2008/0-AU-03], Canadian patent application CA 2718321 entitled \"Human Anti-Mesothelin Monoclonal Antibodies\" [HHS Ref. E-079-2008/0-CA-04], European patent application EP 09726082.2 entitled \"Human Monoclonal Antibody Against Mesothelin\" [HHS Ref. E-079-2008/0-EP-05], U.S. patent application 12/ 934,060 entitled \"Human Anti-Mesothelin Monoclonal Antibodies \" [HHS Ref. E-079-2008/0-US-06], and all related continuing and foreign patents/patent applications for the technology family, to Sanomab, Ltd. The patent rights in these inventions have been assigned to and/or exclusively licensed to the Government of the United States of America. The prospective exclusive evaluation option license territory may be worldwide, and the field of use may be limited to:","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2012/02/01/2012-2213.html","cfr_references":[],"citation":"77 FR 5036","comment_url":null,"comments_close_on":"2012-02-16","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before February 16, 2012 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2012-2213","effective_on":null,"end_page":5037,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2012/02/01/2012-2213.xml","html_url":"https://www.federalregister.gov/documents/2012/02/01/2012-2213/prospective-grant-of-exclusive-license-the-development-of-human-anti-mesothelin-monoclonal","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2012-2213?publication_date=2012-02-01","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2012-02-01/2012-2213/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":67,"last_updated":"2026-09-21 06:15:03 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2012-02-01/pdf/2012-2213.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2012-02213.pdf?1328018086","publication_date":"2012-02-01","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2012/02/01/2012-2213.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"supporting_documents":[],"comments_url":"https://www.regulations.gov/docketBrowser?rpp=50&so=DESC&sb=postedDate&po=0&dct=PS&D=NIH_FRDOC_0001","supporting_documents_count":0,"docket_id":"NIH_FRDOC_0001","regulation_id_number":null,"title":"Recently Posted NIH Rules and Notices.","checked_regulationsdotgov_at":"2012-02-26T19:35:00Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":5036,"subtype":null,"title":"Prospective Grant of Exclusive License: The Development of Human Anti-Mesothelin Monoclonal Antibodies for the Treatment of Human Cancers","toc_doc":"The Development of Human AntiMesothelin Monoclonal Antibodies for the Treatment of Human Cancers","toc_subject":"Prospective Grant of Exclusive License:","topics":[],"type":"Notice","volume":77}